Impact of thalidomide-based induction regimens on PBSC harvest in multiple myeloma patients

被引：0
|
作者：
Lanska, M. [1 ]
Maisnar, V. [1 ]
Radocha, J. [1 ]
Zak, P. [1 ]
Zavrelova, A. [1 ]
Blaha, M. [1 ]
Horacek, J. [1 ]
Doskocilova, K. [1 ]
Maly, J. [1 ]
机构：
[1] Teaching Hosp, Hradec Kralove, Czech Republic
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S151 / S151
页数：1
相关论文
共 50 条
  • [11] Impact of 1q21 Amplification Alone and in Combination with Other Genetic Abnormalities on Outcome in Multiple Myeloma Patients Treated with Thalidomide-Based Regimens
    Grzasko, Norbert
    Hus, Marek
    Morawska, Marta
    Hajek, Roman
    Dmoszynska, Anna
    BLOOD, 2011, 118 (21) : 1240 - 1240
  • [12] VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens
    Lopes-Aguiar, L.
    Delamain, M. T.
    Brito, A. B. C.
    Lourenco, G. J.
    Costa, E. F. D.
    Oliveira, G. B.
    Vassallo, J.
    de Souza, C. A.
    Lima, C. S. P.
    BLOOD CANCER JOURNAL, 2017, 7 : e580 - e580
  • [13] Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma
    Li, Yonghua
    Hou, Jian
    Jiang, Hua
    Wang, Dongxing
    Fu, Weijun
    Yuan, Zhengang
    Chen, Yubao
    Zhou, Lili
    HAEMATOLOGICA, 2007, 92 (09) : 1246 - 1249
  • [14] Early versus delayed autologous stem cell transplantation in patients receiving bortezomib, thalidomide-based induction for multiple myeloma
    Tolhi, S.
    Osmani, S.
    Yafour, N.
    Mohamed, B.
    Arabi, A.
    Bouhass, R.
    Bekadja, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S213 - S213
  • [15] NUMBER OF ADVERSE CYTOGENETIC LESIONS DETECTED BY FISH IS ASSOCIATED WITH PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-BASED REGIMENS
    Grzasko, N.
    Hus, M.
    Morawska, M.
    Chocholska, S.
    Jurczyszyn, A.
    Hajek, R.
    Wojciechowicz, J.
    Kostyra, M.
    Dmoszynska, A.
    HAEMATOLOGICA, 2013, 98 : 338 - 338
  • [16] The International Prognostic Index (IPI) is predictive for survival in refractory or relapsed myeloma patients treated with thalidomide-based regimens.
    Anagnostopoulos, A
    Zervas, K
    Zomas, A
    Pouli, A
    Hamilos, G
    Anagnostopoulos, N
    Dimopoulos, MA
    BLOOD, 2003, 102 (11) : 938A - 938A
  • [17] Activity with Thalidomide-Based Therapy Following Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Young, Trieu
    Chu, Chia-Min
    Xu, Wei
    Anglin, Peter
    Trudel, Suzanne
    Reece, Donna E.
    Chen, Christine
    Kukreti, Vishal
    BLOOD, 2009, 114 (22) : 1483 - 1483
  • [18] Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
    Kukreti, Vishal
    Masih-Khan, Esther
    Young, Trieu
    Chu, Chia-Min
    Jiang, Haiyun
    Trudel, Suzanne
    Chen, Christine
    Jimenez-Zepeda, Victor
    Reece, Donna E.
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (04) : 337 - 338
  • [19] Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens
    Vela-Ojeda, Jorge
    Garcia-Ruiz Esparza, Miriam America
    Majluf-Cruz, Abraham
    Garcia-Chavez, Jaime
    Arcelia Montiel-Cervantes, Laura
    Reyes-Maldonado, Elba
    Hernandez-Caballero, Alvaro
    Guadalupe Rodriguez-Gonzalez, Maria
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (03) : 306 - 312
  • [20] Patterns of progression in myeloma patients treated with thalidomide-based regimens: High incidence of extramedullary progression without serologic relapse.
    Anagnostopoulos, A
    Efstathiou, E
    Hamilos, G
    Zorzou, MP
    Kastritis, E
    Dimopoulos, MA
    BLOOD, 2003, 102 (11) : 454A - 454A
12345